Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
EDINBURGH, United Kingdom, Nov. 14, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
-
Opens Phase III Global Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Focusing Resources on Key Value-Driving Programs of Biliary Tract Cancer and Colorectal...
-
NUC-3373: Favorable Pharmacokinetic Profile Demonstrated NUC-7738: Multiple Anti-Cancer Mechanisms of Action Identified, including Inhibition of the mTOR Pathway BOSTON, Oct. 29, 2019 (GLOBE...
-
Global NuTide:121 Study will Enroll up to 828 Patients and Compare Acelarin plus Cisplatin to Gemcitabine plus Cisplatin Primary Endpoints of Overall Survival and Objective Response Rate Three...
-
EDINBURGH, United Kingdom, Aug. 29, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
-
EDINBURGH, United Kingdom, Aug. 27, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host...
-
Numerous Clinical Data Announcements and Study Initiations Expected in 2019 Current Cash Balance Expected to Fund the Company Into 2021 EDINBURGH, United Kingdom, Aug. 21, 2019 (GLOBE NEWSWIRE)...
-
Imbalances in Prognostic Factors May Have Impacted Analysis Longer-term Follow-up by Study Sponsor is Ongoing to Determine Path Forward Encouraging Survival Trends Observed in Patient Sub-Groups...
-
NUC-7738 is NuCana’s Third ProTide to Enter the Clinic Study Will Enroll Up To 61 Patients with Advanced Solid Tumors EDINBURGH, United Kingdom, July 17, 2019 (GLOBE NEWSWIRE) -- NuCana plc...
-
EDINBURGH, United Kingdom, June 12, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the...